<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Climb Bio Inc — News on 6ix</title>
<link>https://6ix.com/company/climb-bio-inc</link>
<description>Latest news and press releases for Climb Bio Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/climb-bio-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683556a678dffbe2df0e9d5b.webp</url>
<title>Climb Bio Inc</title>
<link>https://6ix.com/company/climb-bio-inc</link>
</image>
<item>
<title>Climb Bio, Inc. Announces $110.0 Million Private Placement</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-inc-announces-dollar1100-million-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-inc-announces-dollar1100-million-private-placement</guid>
<pubDate>Tue, 28 Apr 2026 11:00:00 GMT</pubDate>
<description>WELLESLEY HILLS, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately $110.0 million, before deducting placement agent fees and other offering expenses. The private pl</description>
</item>
<item>
<title>Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-to-host-randd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-to-host-randd-spotlight-webcast-highlighting-budoprutug-and-the-cd19-opportunity-on-may-5-2026</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for</description>
</item>
<item>
<title>Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-announces-fda-fast-track-designation-for-budoprutug-for-the-treatment-of-primary-membranous-nephropathy</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-announces-fda-fast-track-designation-for-budoprutug-for-the-treatment-of-primary-membranous-nephropathy</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Global Phase 2 open-label clinical trial in pMN (PrisMN) enrolling, with initial data anticipated H2 2026 WELLESLEY HILLS, Mass., April 07, 2026 (GLOBE</description>
</item>
<item>
<title>Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates-9</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates-9</guid>
<pubDate>Thu, 05 Mar 2026 12:00:00 GMT</pubDate>
<description>Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026 Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026 Strong financial position with cash runway expected into 2028 WELLESLEY HILLS, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnol</description>
</item>
<item>
<title>Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates </title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates-7</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates-7</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and</description>
</item>
<item>
<title>Climb Bio to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-present-upcoming-investor-120000658</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-present-upcoming-investor-120000658</guid>
<pubDate>Thu, 05 Feb 2026 12:00:00 GMT</pubDate>
<description>WELLESLEY HILLS, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below. Guggenheim's Emerging Outlook: Biotech SummitFormat: Fireside ChatDate: Thursday, February 12, 2026Time: 3:00 – 3:25 p.m. ET Oppenheimer 36th Annual Healthcare Life Sciences Conference Format</description>
</item>
<item>
<title>Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-announces-pipeline-progress-120000449</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-announces-pipeline-progress-120000449</guid>
<pubDate>Thu, 08 Jan 2026 12:00:00 GMT</pubDate>
<description>First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory clearance for SLE IND in China First patients dosed in CLYM116 Phase 1 healthy volunteer study Anticipating a data-rich 2026, with initial readouts from all ongoing budoprutug and CLYM116 studies Strong financial position with cash runway expected into 2028 WELLESLEY HILLS, Mass., Jan. 08,</description>
</item>
<item>
<title>Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-reports-inducement-grant-120000833</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-reports-inducement-grant-120000833</guid>
<pubDate>Tue, 25 Nov 2025 12:00:00 GMT</pubDate>
<description>WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that Climb Bio has granted an inducement equity award to a new employee, pursuant to the Climb Bio’s 2025 Inducement Plan, as amended, as an inducement material to the new employee entering into employment with Climb Bio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement</description>
</item>
<item>
<title>Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-reports-third-quarter-120100061</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-reports-third-quarter-120100061</guid>
<pubDate>Thu, 06 Nov 2025 12:01:00 GMT</pubDate>
<description>PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical trials of budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) ongoing, with initial data from both trials expected in H2 2026 Regulatory clearance obtained to initiate CLYM116 Phase 1 trial; anticipate dosing first subject by year-end, with initial data expected mid-2026 L</description>
</item>
<item>
<title>Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-names-adam-villa-110000945</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-names-adam-villa-110000945</guid>
<pubDate>Tue, 21 Oct 2025 11:00:00 GMT</pubDate>
<description>WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the appointments of Adam Villa as Senior Vice President, Technical Operations, and Ashley Jones as Senior Vice President, People & Workforce Strategy. “We are thrilled to welcome Adam and Ashley to the Climb Bio leadership team,” said Aoife Brennan, M</description>
</item>
<item>
<title>Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-present-data-american-110000430</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-present-data-american-110000430</guid>
<pubDate>Fri, 17 Oct 2025 11:00:00 GMT</pubDate>
<description>Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN) Long-term follow-up clinical data for budoprutug, anti-CD19 monoclonal antibody, support potential for therapeutic benefit in primary membranous nephropathy (pMN) WELLESLEY HILLS, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for pat</description>
</item>
<item>
<title>Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-appoints-susan-altschuller-110000994</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-appoints-susan-altschuller-110000994</guid>
<pubDate>Wed, 01 Oct 2025 11:00:00 GMT</pubDate>
<description>WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the addition of Susan Altschuller, Ph.D., MBA, as Chief Financial Officer. Susan brings over two decades of strategic and financial leadership experience. “Susan is a seasoned biopharmaceutical leader with a strong track record in financial strategy,</description>
</item>
<item>
<title>Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-announces-clym116-preclinical-110000159</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-announces-clym116-preclinical-110000159</guid>
<pubDate>Mon, 29 Sep 2025 11:00:00 GMT</pubDate>
<description>New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody CLYM116 Phase 1 trial initiation expected in Q4 2025, with initial biomarker and dosing interval data anticipated mid-year 2026 Company to host R&D Spotlight Webcast today, September 29, 2025 WELLESLEY HILLS, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediat</description>
</item>
<item>
<title>Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-host-webcast-highlighting-110000847</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-host-webcast-highlighting-110000847</guid>
<pubDate>Thu, 04 Sep 2025 11:00:00 GMT</pubDate>
<description>WELLESLEY HILLS, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the CLYM116 webcast event, which is set for Monday, September 29, 2025, at 8:00 a.m. ET. Climb Bio’s management team will be joined by leading nephrologist, Craig E. Gordon, MD, MS, who has over 20 years of experience treating patients with IgA nephropathy (IgAN). The event will highligh</description>
</item>
<item>
<title>UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-present-upcoming-september-184100456</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-present-upcoming-september-184100456</guid>
<pubDate>Mon, 25 Aug 2025 18:41:00 GMT</pubDate>
<description>WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below. Cantor Global Healthcare ConferenceLocation: New York, NYFormat: Fireside chat and one-on-one investor meetingsDate: Friday, September 5, 2025Time: 10:55 a.m. ET Baird Global Healthcare Conference</description>
</item>
<item>
<title>Climb Bio to Present at Upcoming September 2025 Investor Conferences</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-present-upcoming-september-110000880</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-present-upcoming-september-110000880</guid>
<pubDate>Mon, 25 Aug 2025 11:00:00 GMT</pubDate>
<description>WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below. Cantor Global Healthcare ConferenceLocation: New York, NYFormat: Fireside chat and one-on-one investor meetingsDate: Friday, September 5, 2025Time: 10:55 a.m. ET Baird Global Healthcare Conference</description>
</item>
<item>
<title>eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors</title>
<link>https://6ix.com/company/climb-bio-inc/news/egenesis-appoints-douglas-williams-phd-and-adam-craig-md-phd-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/egenesis-appoints-douglas-williams-phd-and-adam-craig-md-phd-to-its-board-of-directors</guid>
<pubDate>Tue, 19 Aug 2025 12:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., August 19, 2025--eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors</description>
</item>
<item>
<title>Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-reports-second-quarter-110000302</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-reports-second-quarter-110000302</guid>
<pubDate>Tue, 12 Aug 2025 11:00:00 GMT</pubDate>
<description>Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the Coming Weeks Budoprutug Subcutaneous Formulation Demonstrated High Bioavailability and Favorable Tolerability in Non-clinical Studies; Phase 1 Trial Expected to Initiate in the Coming Weeks, with Initial Data Anticipated in First Half 2026 CLYM116 Focused Webcast Event, Including New Preclinical Dat</description>
</item>
<item>
<title>Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-appoints-edgar-d-110000987</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-appoints-edgar-d-110000987</guid>
<pubDate>Wed, 18 Jun 2025 11:00:00 GMT</pubDate>
<description>Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immu</description>
</item>
<item>
<title>Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/climb-bio-inc/news/climb-bio-reports-first-quarter-110000763</link>
<guid isPermaLink="true">https://6ix.com/company/climb-bio-inc/news/climb-bio-reports-first-quarter-110000763</guid>
<pubDate>Wed, 14 May 2025 11:00:00 GMT</pubDate>
<description>Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025 Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer Strong Financial Position, with Cash Runway Expected Through 2027 WELLESLEY HILLS, Mass., May 14, 2025 (GLOBE NEWSWIRE) -</description>
</item>
</channel>
</rss>